This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.